Stuart G Turville

List of Publications by Year
in descending order

81	4,272	117453	123241
papers	citations	34 h-index	61 g-index

103	103	103	5653
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Diversity of receptors binding HIV on dendritic cell subsets. Nature Immunology, 2002, 3, 975-983.	7.0	483
2	Immunodeficiency virus uptake, turnover, and 2-phase transfer in human dendritic cells. Blood, 2004, 103, 2170-2179.	0.6	378
3	HIV gp120 receptors on human dendritic cells. Blood, 2001, 98, 2482-2488.	0.6	185
4	HIV-1 infection of human macrophages directly induces viperin which inhibits viral production. Blood, 2012, 120, 778-788.	0.6	184
5	The influence of cytokines, chemokines and their receptors on HIV-1 replication in monocytes and macrophages. Reviews in Medical Virology, 2003, 13, 39-56.	3.9	162
6	Manipulation of dendritic cell function by viruses. Current Opinion in Microbiology, 2010, 13, 524-529.	2.3	128
7	The role of dendritic cell C-type lectin receptors in HIV pathogenesis. Journal of Leukocyte Biology, 2003, 74, 710-718.	1.5	113
8	N-Linked Glycosylation Facilitates Sialic Acid-Independent Attachment and Entry of Influenza A Viruses into Cells Expressing DC-SIGN or L-SIGN. Journal of Virology, 2011, 85, 2990-3000.	1.5	113
9	SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants. PLoS Medicine, 2021, 18, e1003656.	3.9	109
10	HIV infection of dendritic cells subverts the IFN induction pathway via IRF-1 and inhibits type 1 IFN production. Blood, 2011, 118, 298-308.	0.6	102
11	TNF-Î± Induces Macroautophagy and Regulates MHC Class II Expression in Human Skeletal Muscle Cells. Journal of Biological Chemistry, 2011, 286, 3970-3980.	1.6	98
12	Kinetics of HIV-1 capsid uncoating revealed by single-molecule analysis. ELife, 2018, 7, .	2.8	91
13	Mobilization of HIV Spread by Diaphanous 2 Dependent Filopodia in Infected Dendritic Cells. PLoS Pathogens, 2012, 8, e1002762.	2.1	88
14	Carrageenan/MIV-150 (PC-815), a Combination Microbicide. Sexually Transmitted Diseases, 2007, 34, 9-14.	0.8	79
15	Efficacy of CarraguardÂ®-Based Microbicides In Vivo Despite Variable In Vitro Activity. PLoS ONE, 2008, 3, e3162.	1.1	75
16	Double-Stranded RNA Analog Poly(I:C) Inhibits Human Immunodeficiency Virus Amplification in Dendritic Cells via Type I Interferon-Mediated Activation of APOBEC3G. Journal of Virology, 2009, 83, 884-895.	1.5	70
17	Resolution of de novo HIV production and trafficking in immature dendritic cells. Nature Methods, 2008, 5, 75-85.	9.0	69
18	Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection. Cell Reports Medicine, 2021, 2, 100228.	3.3	66

#	Article	IF	Citations
19	HIV-1â€“infected dendritic cells show 2 phases of gene expression changes, with lysosomal enzyme activity decreased during the second phase. Blood, 2009, 114, 85-94.	0.6	63
20	CD4-Specific Designed Ankyrin Repeat Proteins Are Novel Potent HIV Entry Inhibitors with Unique Characteristics. PLoS Pathogens, 2008, 4, e1000109.	2.1	62
21	HIV-1 Entry and Trans-Infection of Astrocytes Involves CD81 Vesicles. PLoS ONE, 2014, 9, e90620.	1.1	58
22	Inhibition of Two Temporal Phases of HIV-1 Transfer from Primary Langerhans Cells to T Cells: The Role of Langerin. Journal of Immunology, 2014, 193, 2554-2564.	0.4	55
23	Sugar-Binding Proteins Potently Inhibit Dendritic Cell Human Immunodeficiency Virus Type 1 (HIV-1) Infection and Dendritic-Cell-Directed HIV-1 Transfer. Journal of Virology, 2005, 79, 13519-13527.	1.5	53
24	The HIV-1 proviral landscape reveals that Nef contributes to HIV-1 persistence in effector memory CD4+ T cells. Journal of Clinical Investigation, 2022, 132, .	3.9	52
25	Oligomerization of the Macrophage Mannose Receptor Enhances gp120-mediated Binding of HIV-1. Journal of Biological Chemistry, 2009, 284, 11027-11038.	1.6	51
26	The C-type Lectin Langerin Functions as a Receptor for Attachment and Infectious Entry of Influenza A Virus. Journal of Virology, 2016, 90, 206-221.	1.5	51
27	Dynamic Imaging of the Hepatitis C Virus NS5A Protein during a Productive Infection. Journal of Virology, 2014, 88, 3636-3652.	1.5	49
28	Marked structural and functional heterogeneity in CXCR4: Separation of HIVâ€1 and SDFâ€1Î± responses. Immunology and Cell Biology, 2005, 83, 129-143.	1.0	47
29	Discovery of Cyclic Peptide Ligands to the SARS-CoV-2 Spike Protein Using mRNA Display. ACS Central Science, 2021, 7, 1001-1008.	5.3	47
30	The NRTIs Lamivudine, Stavudine and Zidovudine Have Reduced HIV-1 Inhibitory Activity in Astrocytes. PLoS ONE, 2013, 8, e62196.	1.1	46
31	All-Round Manipulation of the Actin Cytoskeleton by HIV. Viruses, 2018, 10, 63.	1.5	46
32	Potent Anti-SARS-CoV-2 Activity by the Natural Product Gallinamide A and Analogues via Inhibition of Cathepsin L. Journal of Medicinal Chemistry, 2022, 65, 2956-2970.	2.9	46
33	Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection. Vaccine, 2021, 39, 5940-5953.	1.7	44
34	Novel RNA Duplex Locks HIV-1 in a Latent State via Chromatin-mediated Transcriptional Silencing. Molecular Therapy - Nucleic Acids, 2015, 4, e261.	2.3	43
35	<scp>SARSâ€CoV</scp>â€2 in human milk is inactivated by Holder pasteurisation but not cold storage. Journal of Paediatrics and Child Health, 2020, 56, 1872-1874.	0.4	42
36	CD4 is expressed by epidermal Langerhans' cells predominantly as covalent dimers. Experimental Dermatology, 2003, 12, 700-711.	1.4	35

#	Article	IF	Citations
37	Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability. Immunity, 2021, 54, 2908-2921.e6.	6.6	35
38	Viruses and Langerhans cells. Immunology and Cell Biology, 2010, 88, 416-423.	1.0	33
39	The Microvesicle Component of HIV-1 Inocula Modulates Dendritic Cell Infection and Maturation and Enhances Adhesion to and Activation of T Lymphocytes. PLoS Pathogens, 2013, 9, e1003700.	2.1	33
40	Evaluation of Commercially Available Viral Transport Medium (VTM) for SARS-CoV-2 Inactivation and Use in Point-of-Care (POC) Testing. Viruses, 2020, 12, 1208.	1.5	33
41	COVIDâ€19 vaccine failure in chronic lymphocytic leukaemia and monoclonal Bâ€lymphocytosis; humoural and cellular immunity. British Journal of Haematology, 2022, 197, 41-51.	1.2	32
42	Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia. Nature Microbiology, 2022, 7, 896-908.	5.9	32
43	Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ TÂcell responses. Cell Reports, 2022, 38, 110345.	2.9	30
44	Bitter-sweet symphony: defining the role of dendritic cell gp120 receptors in HIV infection. Journal of Clinical Virology, 2001, 22, 229-239.	1.6	29
45	Antiviral cyclic peptides targeting the main protease of SARS-CoV-2. Chemical Science, 2022, 13, 3826-3836.	3.7	29
46	SARS Coronavirus-2 Microneutralisation and Commercial Serological Assays Correlated Closely for Some but Not All Enzyme Immunoassays. Viruses, 2021, 13, 247.	1.5	28
47	HIV-1 and SIV Predominantly Use CCR5 Expressed on a Precursor Population to Establish Infection in T Follicular Helper Cells. Frontiers in Immunology, 2017, 8, 376.	2.2	26
48	Marked differences in the structures and protein associations of lymphocyte and monocyte CD4: Resolution of a novel CD4 isoform. Immunology and Cell Biology, 2006, 84, 154-165.	1.0	24
49	A Fusion Inhibitor Prevents Spread of Immunodeficiency Viruses, but Not Activation of Virus-Specific T Cells, by Dendritic Cells. Journal of Virology, 2008, 82, 5329-5339.	1.5	24
50	SARS-CoV-2 Omicron variant escapes neutralizing antibodies and TÂcell responses more efficiently than other variants in mild COVID-19 convalescents. Cell Reports Medicine, 2022, 3, 100651.	3.3	24
51	Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies. MAbs, 2021, 13, 1922134.	2.6	22
52	Virus isolation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for diagnostic and research purposes. Pathology, 2020, 52, 760-763.	0.3	21
53	<scp>HIV</scp> infection is influenced by dynamin at 3 independent points in the viral life cycle. Traffic, 2017, 18, 392-410.	1.3	18
54	Fluorescence Biosensor for Real-Time Interaction Dynamics of Host Proteins with HIV-1 Capsid Tubes. ACS Applied Materials & Interfaces, 2019, 11, 34586-34594.	4.0	18

#	Article	IF	Citations
55	Slamming the door on unwanted guests: why preemptive strikes at the mucosa may be the best strategy against HIV. Journal of Leukocyte Biology, 2006, 80, 1076-1083.	1.5	17
56	Revising the Role of Myeloid cells in HIV Pathogenesis. Current HIV/AIDS Reports, 2013, 10, 3-11.	1.1	15
57	Male Circumcision and HIV Transmission; What Do We Know?. Open AIDS Journal, 2014, 8, 31-44.	0.1	15
58	Host glycocalyx captures HIV proximal to the cell surface via oligomannose-GlcNAc glycan-glycan interactions to support viral entry. Cell Reports, 2022, 38, 110296.	2.9	12
59	Lymphocyte???dendritic cell interactions and mucosal acquisition of SIV/HIV infection. Current Opinion in HIV and AIDS, 2006, 1, 3-9.	1.5	11
60	Self-Assembly of Fluorescent HIV Capsid Spheres for Detection of Capsid Binders. Langmuir, 2020, 36, 3624-3632.	1.6	11
61	Fluorescence Microscopy Assay to Measure HIV-1 Capsid Uncoating Kinetics in vitro. Bio-protocol, 2019, 9, e3297.	0.2	10
62	Virtual screening and in vitro validation of natural compound inhibitors against SARS-CoV-2 spike protein. Bioorganic Chemistry, 2022, 119, 105574.	2.0	10
63	Analysis and dissociation of antiâ€HIV effects of shRNA to CCR5 and the fusion inhibitor C46. Journal of Gene Medicine, 2018, 20, e3006.	1.4	9
64	Embedding of HIV Egress within Cortical F-Actin. Pathogens, 2022, 11, 56.	1.2	9
65	Patients with treated indolent lymphomas immunized with <scp>BNT162b2</scp> have reduced antiâ€spike neutralizing <scp>IgG</scp> to <scp>SARSâ€CoV</scp>â€2 variants, but preserved antigenâ€specific T cell responses. American Journal of Hematology, 2023, 98, 131-139.	2.0	9
66	High-Titer Neutralizing Antibodies against the SARS-CoV-2 Delta Variant Induced by Alhydroxyquim-II-Adjuvanted Trimeric Spike Antigens. Microbiology Spectrum, 2022, 10, e0169521.	1.2	8
67	Blocking of HIV entry through CD44â€“hyaluronic acid interactions. Immunology and Cell Biology, 2014, 92, 735-736.	1.0	7
68	The feasibility of incorporating Vpx into lentiviral gene therapy vectors. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16066.	1.8	6
69	Delivery of gene therapy to resting immune cells for an HIV cure. Current Opinion in HIV and AIDS, 2019, 14, 129-136.	1.5	6
70	C-Type Lectin-HIV Attachment on Dendritic Cells: Innate Immune Recognition and Processing or Mediators of HIV Transmission?. Trends in Glycoscience and Glycotechnology, 2002, 14, 255-271.	0.0	6
71	Modular Lentiviral Vectors for Highly Efficient Transgene Expression in Resting Immune Cells. Viruses, 2021, 13, 1170.	1.5	5
72	HIV Infection of Dendritic Cells. Methods in Molecular Biology, 2014, 1087, 221-232.	0.4	5

#	Article	IF	Citations
73	Rapid HIV-1 Capsid Interaction Screening Using Fluorescence Fluctuation Spectroscopy. Analytical Chemistry, 2021, 93, 3786-3793.	3.2	4
74	Protocol for SARS-CoV-2 post-vaccine surveillance study in Australian adults and children with cancer: an observational study of safety and serological and immunological response to SARS-CoV-2 vaccination (SerOzNET). BMC Infectious Diseases, 2022, 22, 70.	1.3	4
75	Persistent highâ€level shedding of cultivable SARSâ€CoVâ€2 Delta virus 33 days after onset of COVIDâ€19 in a hospitalized patient with pneumonia. Journal of Medical Virology, 2022, 94, 4043-4046.	2.5	4
76	Mechanisms for Controlling HIV-1 Infection: A Gene Therapy Approach. , 0, , .		3
77	Long-Term Persistence of Neutralizing Memory B Cells in SARS-CoV-2. SSRN Electronic Journal, 0, , .	0.4	1
78	Resolving the Sites of HIV Entry: Dynamin Networks Hold the Key. Journal of Cell Signaling, 2017, 02, .	0.3	0
79	Binding and Uptake of HIV by Dendritic Cellsand Transfer to T Lymphocytes: Implicationsfor Pathogenesis. , 2007, , 381-404.		0
80	Imaging of HIV entry and egress. Microbiology Australia, 2014, 35, 107.	0.1	0
81	Efficacy of Vaccine BNT162b2 (Pfizer-BioNTech) in Individuals with Waldenstrom's Macroglobulinemia and Follicular Lymphoma in Australia. Blood, 2021, 138, 816-816.	0.6	0